Brief: Windtree Therapeutics Inc - Interim Analysis To Assess Safety, Tolerability, And Preliminary Efficacy
30/06/2025 14:29
Windtree Therapeutics Inc WINT.O: WINDTREE THERAPEUTICS INC - INTERIM ANALYSIS TO ASSESS SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY WINDTREE THERAPEUTICS INC - REACHES PLANNED ENROLLMENT OF 20 PATIENTS FOR SEISMIC C STUDY WINDTREE THERAPEUTICS INC - DATA EXPECTED TO BE USEFUL FOR END OF PHASE 2 MEETING WITH FDA Source text: ID:nGNX86K8CL Further company coverage: WINT.O
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study